5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Anaphylactic O
reactions O
and O
allergic O
skin O
reactions O
, O
serious O
, O
occasionally O
fatal O
, O
may O
occur O
after O
first O
dose O
( O
4 O
, O
5.7 O
) O
* O
Hematologic O
( O
including O
agranulocytosis O
, O
thrombocytopenia O
) O
, O
and O
renal O
toxicities O
may O
occur O
after O
multiple O
doses O
( O
5.6 O
) O
* O
Hepatotoxicity O
: O
Severe O
, O
and O
sometimes O
fatal O
, O
hepatotoxicity O
has O
been O
reported O
. O

Discontinue O
immediately O
if O
signs O
and O
symptoms O
of O
hepatitis O
occur O
( O
5.8 O
) O
* O
Clostridium O
difficile O
-associated O
colitis O
: O
evaluate O
if O
diarrhea O
occurs O
( O
5.9 O
) O
* O
Prolongation O
of O
the O
QT O
interval O
and O
isolated O
cases O
of O
torsade O
de O
pointes O
have O
been O
reported O
. O

Avoid O
use O
in O
patients O
with O
known O
prolongation O
, O
those O
with O
hypokalemia O
, O
and O
with O
other O
drugs O
that O
prolong O
the O
QT O
interval O
( O
5.10 O
, O
8.5 O
) O
5.1 O
Disabling O
and O
Potentially O
Irreversible O
Serious O
Adverse O
Reactions O
Including O
Tendinitis O
and O
Tendon O
Rupture O
, O
Peripheral O
Neuropathy O
, O
and O
Central O
Nervous O
System O
Effects O
Fluoroquinolones O
, O
including O
LEVAQUIN O
, O
have O
been O
associated O
with O
disabling O
and O
potentially O
irreversible O
serious O
adverse O
reactions O
from O
different O
body O
systems O
that O
can O
occur O
together O
in O
the O
same O
patient O
. O

Commonly O
seen O
adverse O
reactions O
include O
tendinitis B-OSE_Labeled_AE
, O
tendon B-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
and O
central B-OSE_Labeled_AE
nervous I-OSE_Labeled_AE
system I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
( O
hallucinations B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
severe O
headaches B-OSE_Labeled_AE
, O
and O
confusion B-OSE_Labeled_AE
) O
. O

These O
reactions O
can O
occur O
within O
hours O
to O
weeks O
after O
starting O
LEVAQUIN O
. O

Patients O
of O
any O
age O
or O
without O
pre-existing O
risk O
factors O
have O
experienced O
these O
adverse O
reactions O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
, O
5.3 O
, O
5.4 O
) O
] O
. O

Discontinue O
LEVAQUIN O
immediately O
at O
the O
first O
signs O
or O
symptoms O
of O
any O
serious O
adverse O
reaction O
. O

In O
addition O
, O
avoid O
the O
use O
of O
fluoroquinolones O
, O
including O
LEVAQUIN O
, O
in O
patients O
who O
have O
experienced O
any O
of O
these O
serious O
adverse O
reactions O
associated O
with O
fluoroquinolones O
. O

5.2 O
Tendinitis O
and O
Tendon O
Rupture O
Fluoroquinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
, O
have O
been O
associated O
with O
an O
increased O
risk O
of O
tendinitis B-OSE_Labeled_AE
and O
tendon B-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
in O
all O
ages O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
and O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

This O
adverse O
reaction O
most O
frequently O
involves O
the O
Achilles O
tendon O
And O
has O
also O
been O
reported O
with O
the O
rotator O
cuff O
( O
the O
shoulder O
) O
, O
the O
hand O
, O
the O
biceps O
, O
the O
thumb O
, O
and O
other O
tendon O
sites O
. O

Tendinitis B-OSE_Labeled_AE
or O
tendon B-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
can O
occur O
within O
hours O
or O
days O
of O
starting O
LEVAQUIN O
or O
as O
long O
as O
several O
months O
after O
completion O
of O
fluoroquinolone O
therapy O
. O

Tendinitis B-OSE_Labeled_AE
and O
tendon B-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
can O
occur O
bilaterally O
. O

The O
risk O
of O
developing O
fluoroquinolone B-OSE_Labeled_AE
- I-OSE_Labeled_AE
associated I-OSE_Labeled_AE
tendinitis I-OSE_Labeled_AE
and O
tendon B-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
is O
increased O
in O
patients O
over O
60 O
years O
of O
age O
, O
in O
those O
taking O
corticosteroid O
drugs O
, O
and O
in O
patients O
with O
kidney O
, O
heart O
or O
lung O
transplants O
. O

Other O
factors O
that O
may O
independently O
increase O
the O
risk O
of O
tendon B-NonOSE_AE
rupture I-NonOSE_AE
include O
strenuous O
physical O
activity O
, O
renal B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
and O
previous O
tendon B-Not_AE_Candidate
disorders I-Not_AE_Candidate
such O
as O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
. O

Tendinitis B-OSE_Labeled_AE
and O
tendon B-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
taking O
fluoroquinolones O
who O
do O
not O
have O
the O
above O
risk O
factors O
. O

Discontinue O
LEVAQUIN O
( O
r O
) O
immediately O
if O
the O
patient O
experiences O
pain B-NonOSE_AE
, O
swelling O
, O
inflammation O
or O
rupture O
of I-NonOSE_AE
a I-NonOSE_AE
tendon I-NonOSE_AE
. O

Patients O
should O
be O
advised O
to O
rest O
at O
the O
first O
sign O
of O
tendinitis B-NonOSE_AE
or O
tendon B-NonOSE_AE
rupture I-NonOSE_AE
, O
and O
to O
contact O
their O
healthcare O
provider O
regarding O
changing O
to O
a O
non-quinolone O
antimicrobial O
drug O
. O

Avoid O
LEVAQUIN O
in O
patients O
who O
have O
a O
history O
of O
tendon B-Not_AE_Candidate
disorders I-Not_AE_Candidate
or O
tendon B-Not_AE_Candidate
rupture I-Not_AE_Candidate
[ O
see O
Adverse O
Reactions O
( O
6.3 O
) O
; O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.3 O
Peripheral O
Neuropathy O
Fluoroquinolones O
, O
including O
LEVAQUIN O
, O
have O
been O
associated O
with O
an O
increased O
risk O
of O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
. O

Cases O
of O
sensory B-OSE_Labeled_AE
or O
sensorimotor O
axonal I-OSE_Labeled_AE
polyneuropathy I-OSE_Labeled_AE
affecting O
small O
and/or O
large O
axons O
resulting O
in O
paresthesias B-NonOSE_AE
, O
hypoesthesias B-NonOSE_AE
, O
dysesthesias B-NonOSE_AE
and O
weakness B-NonOSE_AE
have O
been O
reported O
in O
patients O
receiving O
fluoroquinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
. O

Symptoms O
may O
occur O
soon O
after O
initiation O
of O
LEVAQUIN O
( O
r O
) O
and O
may O
be O
irreversible O
in O
some O
patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
, O
6.2 O
) O
] O
. O

Discontinue O
LEVAQUIN O
( O
r O
) O
immediately O
if O
the O
patient O
experiences O
symptoms O
of O
neuropathy B-NonOSE_AE
including O
pain B-NonOSE_AE
, O
burning B-NonOSE_AE
, O
tingling B-NonOSE_AE
, O
numbness B-NonOSE_AE
, O
and/or O
weakness B-NonOSE_AE
or O
other O
alterations B-NonOSE_AE
of I-NonOSE_AE
sensation I-NonOSE_AE
including O
light O
touch O
, O
pain O
, O
temperature O
, O
position O
sense O
, O
and O
vibratory B-NonOSE_AE
sensation I-NonOSE_AE
. O

Avoid O
fluoroquinolones O
, O
including O
LEVAQUIN O
, O
in O
patients O
who O
have O
previously O
experienced O
peripheral B-Not_AE_Candidate
neuropathy I-Not_AE_Candidate
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
, O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.4 O
Central O
Nervous O
System O
Effects O
Fluoroquinolones O
, O
including O
LEVAQUIN O
, O
have O
been O
associated O
with O
an O
increased O
risk O
of O
central B-OSE_Labeled_AE
nervous I-OSE_Labeled_AE
system I-OSE_Labeled_AE
( I-OSE_Labeled_AE
CNS I-OSE_Labeled_AE
) I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
, O
including O
convulsions B-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
psychoses I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
intracranial I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
( O
including O
pseudotumor B-OSE_Labeled_AE
cerebri I-OSE_Labeled_AE
) O
. O

Fluoroquinolones O
may O
also O
cause O
central B-OSE_Labeled_AE
nervous I-OSE_Labeled_AE
system I-OSE_Labeled_AE
stimulation I-OSE_Labeled_AE
which O
may O
lead O
to O
tremors B-OSE_Labeled_AE
, O
restlessness B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
lightheadedness B-OSE_Labeled_AE
, O
confusion B-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
, O
paranoia B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
nightmares B-OSE_Labeled_AE
, O
and O
insomnia B-OSE_Labeled_AE
. O

Suicidal B-OSE_Labeled_AE
thoughts I-OSE_Labeled_AE
, O
and O
attempted B-OSE_Labeled_AE
or I-OSE_Labeled_AE
completed I-OSE_Labeled_AE
suicide I-OSE_Labeled_AE
may O
also O
occur O
, O
especially O
in O
patients O
with O
a O
medical O
history O
of O
depression B-Not_AE_Candidate
, O
or O
an O
underlying O
risk O
factor O
for O
depression B-Not_AE_Candidate
. O

These O
reactions O
may O
occur O
following O
the O
first O
dose O
. O

If O
these O
reactions O
occur O
in O
patients O
receiving O
LEVAQUIN O
( O
r O
) O
, O
discontinue O
LEVAQUIN O
and O
institute O
appropriate O
measures O
. O

As O
with O
other O
fluoroquinolones O
, O
LEVAQUIN O
( O
r O
) O
should O
be O
used O
with O
caution O
in O
patients O
with O
a O
known O
or O
suspected O
central B-Not_AE_Candidate
nervous I-Not_AE_Candidate
system I-Not_AE_Candidate
( I-Not_AE_Candidate
CNS I-Not_AE_Candidate
) I-Not_AE_Candidate
disorder I-Not_AE_Candidate
that O
may O
predispose O
them O
to O
seizures B-NonOSE_AE
or O
lower B-NonOSE_AE
the I-NonOSE_AE
seizure I-NonOSE_AE
threshold I-NonOSE_AE
( O
e.g. O
, O
severe O
cerebral B-Not_AE_Candidate
arteriosclerosis I-Not_AE_Candidate
, O
epilepsy B-Not_AE_Candidate
) O
or O
in O
the O
presence O
of O
other O
risk O
factors O
that O
may O
predispose O
them O
to O
seizures B-Not_AE_Candidate
or O
lower B-Not_AE_Candidate
the I-Not_AE_Candidate
seizure I-Not_AE_Candidate
threshold I-Not_AE_Candidate
( O
e.g. O
, O
certain O
drug O
therapy O
, O
renal B-Not_AE_Candidate
dysfunction I-Not_AE_Candidate
) O
. O

[ O
see O
Adverse O
Reactions O
( O
6 O
) O
; O
Drug O
Interactions O
( O
7.4 O
, O
7.5 O
) O
; O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.5 O
Exacerbation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Myasthenia I-OSE_Labeled_AE
Gravis I-OSE_Labeled_AE
Fluoroquinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
, O
have O
neuromuscular O
blocking O
activity O
and O
may O
exacerbate B-OSE_Labeled_AE
muscle I-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
in O
patients O
with O
myasthenia B-Not_AE_Candidate
gravis I-Not_AE_Candidate
. O

Postmarketing O
serious O
adverse O
reactions O
including O
deaths B-NonOSE_AE
and O
requirement O
for O
ventilatory O
support O
, O
have O
been O
associated O
with O
fluoroquinolone O
use O
in O
patients O
with O
myasthenia B-Not_AE_Candidate
gravis I-Not_AE_Candidate
. O

Avoid O
LEVAQUIN O
( O
r O
) O
in O
patients O
with O
a O
known O
history O
of O
myasthenia B-Not_AE_Candidate
gravis I-Not_AE_Candidate
[ O
see O
Adverse O
Reactions O
( O
6.3 O
) O
; O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.6 O
Other O
Serious O
and O
Sometimes O
Fatal O
Adverse O
Reactions O
Other O
serious O
and O
sometimes O
fatal B-NonOSE_AE
adverse O
reactions O
, O
some O
due O
to O
hypersensitivity B-OSE_Labeled_AE
, O
and O
some O
due O
to O
uncertain O
etiology O
, O
have O
been O
reported O
rarely O
in O
patients O
receiving O
therapy O
with O
fluoroquinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
. O

These O
events O
may O
be O
severe O
and O
generally O
occur O
following O
the O
administration O
of O
multiple O
doses O
. O

Clinical O
manifestations O
may O
include O
one O
or O
more O
of O
the O
following O
: O
* O
fever B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
or O
severe O
dermatologic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
e.g. O
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
) O
; O
* O
vasculitis B-OSE_Labeled_AE
; O
arthralgia B-OSE_Labeled_AE
; O
myalgia B-OSE_Labeled_AE
; O
serum B-OSE_Labeled_AE
sickness I-OSE_Labeled_AE
; O
* O
allergic B-OSE_Labeled_AE
pneumonitis I-OSE_Labeled_AE
; O
* O
interstitial B-OSE_Labeled_AE
nephritis I-OSE_Labeled_AE
; O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
insufficiency O
or O
failure I-OSE_Labeled_AE
; O
* O
hepatitis B-OSE_Labeled_AE
; O
jaundice B-OSE_Labeled_AE
; O
acute B-OSE_Labeled_AE
hepatic I-OSE_Labeled_AE
necrosis O
or O
failure I-OSE_Labeled_AE
; O
* O
anemia B-OSE_Labeled_AE
, O
including O
hemolytic B-OSE_Labeled_AE
and O
aplastic B-OSE_Labeled_AE
; O
thrombocytopenia B-OSE_Labeled_AE
, O
including O
thrombotic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
; O
leukopenia B-OSE_Labeled_AE
; O
agranulocytosis B-OSE_Labeled_AE
; O
pancytopenia B-OSE_Labeled_AE
; O
and/or O
other O
hematologic B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
. O

Discontinue O
LEVAQUIN O
immediately O
at O
the O
first O
appearance O
of O
skin B-NonOSE_AE
rash I-NonOSE_AE
, O
jaundice B-NonOSE_AE
, O
or O
any O
other O
sign O
of O
hypersensitivity B-NonOSE_AE
and O
institute O
supportive O
measures O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
; O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.7 O
Hypersensitivity O
Reactions O
Serious O
and O
occasionally O
fatal B-NonOSE_AE
hypersensitivity B-OSE_Labeled_AE
and/or O
anaphylactic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
receiving O
therapy O
with O
fluoroquinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
. O

These O
reactions O
often O
occur O
following O
the O
first O
dose O
. O

Some O
reactions O
have O
been O
accompanied O
by O
cardiovascular B-NonOSE_AE
collapse I-NonOSE_AE
, O
hypotension B-NonOSE_AE
/ O
shock B-NonOSE_AE
, O
seizure B-NonOSE_AE
, O
loss B-NonOSE_AE
of I-NonOSE_AE
consciousness I-NonOSE_AE
, O
tingling B-NonOSE_AE
, O
angioedema B-NonOSE_AE
( O
including O
tongue B-NonOSE_AE
, O
laryngeal O
, O
throat O
, O
or O
facial O
edema/ O
swelling I-NonOSE_AE
) O
, O
airway B-NonOSE_AE
obstruction I-NonOSE_AE
( O
including O
bronchospasm B-NonOSE_AE
, O
shortness B-NonOSE_AE
of I-NonOSE_AE
breath I-NonOSE_AE
, O
and O
acute B-NonOSE_AE
respiratory I-NonOSE_AE
distress I-NonOSE_AE
) O
, O
dyspnea B-NonOSE_AE
, O
urticaria B-NonOSE_AE
, O
itching B-NonOSE_AE
, O
and O
other O
serious O
skin B-NonOSE_AE
reactions I-NonOSE_AE
. O

LEVAQUIN O
( O
r O
) O
should O
be O
discontinued O
immediately O
at O
the O
first O
appearance O
of O
a O
skin B-NonOSE_AE
rash I-NonOSE_AE
or O
any O
other O
sign O
of O
hypersensitivity B-NonOSE_AE
. O

Serious O
acute O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
may O
require O
treatment O
with O
epinephrine O
and O
other O
resuscitative O
measures O
, O
including O
oxygen O
, O
intravenous O
fluids O
, O
antihistamines O
, O
corticosteroids O
, O
pressor O
amines O
, O
and O
airway O
management O
, O
as O
clinically O
indicated O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
; O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.8 O
Hepatotoxicity O
Post-marketing O
reports O
of O
severe O
hepatotoxicity B-OSE_Labeled_AE
( O
including O
acute B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
and O
fatal B-NonOSE_AE
events O
) O
have O
been O
received O
for O
patients O
treated O
with O
LEVAQUIN O
( O
r O
) O
. O

No O
evidence O
of O
serious O
drug B-NonOSE_AE
- I-NonOSE_AE
associated I-NonOSE_AE
hepatotoxicity I-NonOSE_AE
was O
detected O
in O
clinical O
trials O
of O
over O
7,000 O
patients O
. O

Severe O
hepatotoxicity B-OSE_Labeled_AE
generally O
occurred O
within O
14 O
days O
of O
initiation O
of O
therapy O
and O
most O
cases O
occurred O
within O
6 O
days O
. O

Most O
cases O
of O
severe O
hepatotoxicity B-NonOSE_AE
were O
not O
associated O
with O
hypersensitivity B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
. O

The O
majority O
of O
fatal B-NonOSE_AE
hepatotoxicity B-NonOSE_AE
reports O
occurred O
in O
patients O
65 O
years O
of O
age O
or O
older O
and O
most O
were O
not O
associated O
with O
hypersensitivity B-NonOSE_AE
. O

LEVAQUIN O
( O
r O
) O
should O
be O
discontinued O
immediately O
if O
the O
patient O
develops O
signs O
and O
symptoms O
of O
hepatitis B-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
; O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.9 O
Clostridium O
difficile-Associated O
Diarrhea O
Clostridium B-OSE_Labeled_AE
difficile I-OSE_Labeled_AE
- I-OSE_Labeled_AE
associated I-OSE_Labeled_AE
diarrhea I-OSE_Labeled_AE
( I-OSE_Labeled_AE
CDAD I-OSE_Labeled_AE
) O
has O
been O
reported O
with O
use O
of O
nearly O
all O
antibacterial O
agents O
, O
including O
LEVAQUIN O
( O
r O
) O
, O
and O
may O
range O
in O
severity O
from O
mild O
diarrhea B-OSE_Labeled_AE
to O
fatal B-NonOSE_AE
colitis B-OSE_Labeled_AE
. O

Treatment O
with O
antibacterial O
agents O
alters B-NonOSE_AE
the I-NonOSE_AE
normal I-NonOSE_AE
flora I-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
colon I-NonOSE_AE
leading O
to O
overgrowth B-NonOSE_AE
of I-NonOSE_AE
C I-NonOSE_AE
. I-NonOSE_AE
difficile I-NonOSE_AE
. O

C B-NonOSE_AE
. I-NonOSE_AE
difficile I-NonOSE_AE
produces O
toxins O
A O
and O
B O
which O
contribute O
to O
the O
development O
of O
CDAD B-NonOSE_AE
. O

Hypertoxin O
producing O
strains O
of O
C B-NonOSE_AE
. I-NonOSE_AE
difficile I-NonOSE_AE
cause O
increased O
morbidity O
and O
mortality B-NonOSE_AE
, O
as O
these O
infections B-NonOSE_AE
can O
be O
refractory O
to O
antimicrobial O
therapy O
and O
may O
require O
colectomy O
. O

CDAD B-NonOSE_AE
must O
be O
considered O
in O
all O
patients O
who O
present O
with O
diarrhea B-NonOSE_AE
following O
antibiotic O
use O
. O

Careful O
medical O
history O
is O
necessary O
since O
CDAD B-NonOSE_AE
has O
been O
reported O
to O
occur O
over O
two O
months O
after O
the O
administration O
of O
antibacterial O
agents O
. O

If O
CDAD B-NonOSE_AE
is O
suspected O
or O
confirmed O
, O
ongoing O
antibiotic O
use O
not O
directed O
against O
C B-NonOSE_AE
. I-NonOSE_AE
difficile I-NonOSE_AE
may O
need O
to O
be O
discontinued O
. O

Appropriate O
fluid O
and O
electrolyte O
management O
, O
protein O
supplementation O
, O
antibiotic O
treatment O
of O
C B-NonOSE_AE
. I-NonOSE_AE
difficile I-NonOSE_AE
, O
and O
surgical O
evaluation O
should O
be O
instituted O
as O
clinically O
indicated O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
, O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.10 O
Prolongation O
of O
the O
QT O
Interval O
Some O
fluoroquinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
, O
have O
been O
associated O
with O
prolongation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
QT I-OSE_Labeled_AE
interval I-OSE_Labeled_AE
on O
the O
electrocardiogram O
and O
infrequent O
cases O
of O
arrhythmia B-OSE_Labeled_AE
. O

Rare O
cases O
of O
torsade B-OSE_Labeled_AE
de I-OSE_Labeled_AE
pointes I-OSE_Labeled_AE
have O
been O
spontaneously O
reported O
during O
postmarketing O
surveillance O
in O
patients O
receiving O
fluoroquinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
. O

LEVAQUIN O
( O
r O
) O
should O
be O
avoided O
in O
patients O
with O
known O
prolongation B-Not_AE_Candidate
of I-Not_AE_Candidate
the I-Not_AE_Candidate
QT I-Not_AE_Candidate
interval I-Not_AE_Candidate
, O
patients O
with O
uncorrected O
hypokalemia B-Not_AE_Candidate
, O
and O
patients O
receiving O
Class O
IA O
( O
quinidine O
, O
procainamide O
) O
, O
or O
Class O
III O
( O
amiodarone O
, O
sotalol O
) O
antiarrhythmic O
agents O
. O

Elderly O
patients O
may O
be O
more O
susceptible O
to O
drug B-NonOSE_AE
- I-NonOSE_AE
associated I-NonOSE_AE
effects I-NonOSE_AE
on I-NonOSE_AE
the I-NonOSE_AE
QT I-NonOSE_AE
interval I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.3 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
, O
and O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.11 O
Musculoskeletal O
Disorders O
in O
Pediatric O
Patients O
and O
Arthropathic O
Effects O
in O
Animals O
LEVAQUIN O
( O
r O
) O
is O
indicated O
in O
pediatric O
patients O
( O
6 O
months O
of O
age O
and O
older O
) O
only O
for O
the O
prevention O
of O
inhalational B-Not_AE_Candidate
anthrax I-Not_AE_Candidate
( O
post-exposure O
) O
and O
for O
plague B-Not_AE_Candidate
[ O
see O
Indications O
and O
Usage O
( O
1.7 O
, O
1.8 O
) O
] O
. O

An O
increased O
incidence O
of O
musculoskeletal B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
( O
arthralgia B-OSE_Labeled_AE
, O
arthritis B-OSE_Labeled_AE
, O
tendinopathy B-OSE_Labeled_AE
, O
and O
gait B-OSE_Labeled_AE
abnormality I-OSE_Labeled_AE
) O
compared O
to O
controls O
has O
been O
observed O
in O
pediatric O
patients O
receiving O
LEVAQUIN O
( O
r O
) O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.4 O
) O
] O
. O

In O
immature O
rats O
and O
dogs O
, O
the O
oral O
and O
intravenous O
administration O
of O
levofloxacin O
resulted O
in O
increased O
osteochondrosis B-NonOSE_AE
. O

Histopathological O
examination O
of O
the O
weight-bearing O
joints O
of O
immature O
dogs O
dosed O
with O
levofloxacin O
revealed O
persistent O
lesions B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
cartilage I-NonOSE_AE
. O

Other O
fluoroquinolones O
also O
produce O
similar O
erosions B-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
weight I-NonOSE_AE
- I-NonOSE_AE
bearing I-NonOSE_AE
joints I-NonOSE_AE
and O
other O
signs O
of O
arthropathy B-NonOSE_AE
in O
immature O
animals O
of O
various O
species O
[ O
see O
Animal O
Toxicology O
and/or O
Pharmacology O
( O
13.2 O
) O
] O
. O

5.12 O
Blood O
Glucose O
Disturbances O
As O
with O
other O
fluoroquinolones O
, O
disturbances B-OSE_Labeled_AE
of I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
, O
including O
symptomatic O
hyper B-OSE_Labeled_AE
- O
and O
hypo O
glycemia I-OSE_Labeled_AE
, O
have O
been O
reported O
with O
LEVAQUIN O
( O
r O
) O
, O
usually O
in O
diabetic O
patients O
receiving O
concomitant O
treatment O
with O
an O
oral O
hypoglycemic B-NonOSE_AE
agent I-NonOSE_AE
( O
e.g. O
, O
glyburide O
) O
or O
with O
insulin O
. O

In O
these O
patients O
, O
careful O
monitoring O
of O
blood O
glucose O
is O
recommended O
. O

If O
a O
hypoglycemic B-NonOSE_AE
reaction O
occurs O
in O
a O
patient O
being O
treated O
with O
LEVAQUIN O
( O
r O
) O
, O
LEVAQUIN O
( O
r O
) O
should O
be O
discontinued O
and O
appropriate O
therapy O
should O
be O
initiated O
immediately O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
; O
Drug O
Interactions O
( O
7.3 O
) O
; O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.13 O
Photosensitivity/Phototoxicity O
Moderate O
to O
severe O
photosensitivity B-OSE_Labeled_AE
/phototoxicity O
reactions I-OSE_Labeled_AE
, O
the O
latter O
of O
which O
may O
manifest O
as O
exaggerated O
sunburn B-NonOSE_AE
reactions I-NonOSE_AE
( O
e.g. O
, O
burning B-NonOSE_AE
, O
erythema B-NonOSE_AE
, O
exudation B-NonOSE_AE
, O
vesicles B-NonOSE_AE
, O
blistering B-NonOSE_AE
, O
edema B-NonOSE_AE
) O
involving O
areas O
exposed O
to O
light O
( O
typically O
the O
face O
, O
`` O
V O
'' O
area O
of O
the O
neck O
, O
extensor O
surfaces O
of O
the O
forearms O
, O
dorsa O
of O
the O
hands O
) O
, O
can O
be O
associated O
with O
the O
use O
of O
fluoroquinolones O
after O
sun O
or O
UV O
light O
exposure O
. O

Therefore O
, O
excessive O
exposure O
to O
these O
sources O
of O
light O
should O
be O
avoided O
. O

Drug O
therapy O
should O
be O
discontinued O
if O
photosensitivity B-NonOSE_AE
/ O
phototoxicity B-NonOSE_AE
occurs O
[ O
see O
Adverse O
Reactions O
( O
6.3 O
) O
; O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.14 O
Development O
of O
Drug O
Resistant O
Bacteria O
Prescribing O
LEVAQUIN O
( O
r O
) O
in O
the O
absence O
of O
a O
proven O
or O
strongly O
suspected O
bacterial B-NonOSE_AE
infection I-NonOSE_AE
or O
a O
prophylactic O
indication O
is O
unlikely O
to O
provide O
benefit O
to O
the O
patient O
and O
increases O
the O
risk O
of O
the O
development B-OSE_Labeled_AE
of I-OSE_Labeled_AE
drug I-OSE_Labeled_AE
- I-OSE_Labeled_AE
resistant I-OSE_Labeled_AE
bacteria I-OSE_Labeled_AE
[ O
see O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

